In our study, the features of vascular normalisation (pericyte coverage and tumour perfusion) are still in the high range, either in BMP9‐overexpressing HBV‐infected HCC xenografts (Figure 4) or in the intratumourally delivered BMP9 treatment (Figure 6), which is different from VEGF inhibitors. This evidence concerns the gene VEGFA and hepatocellular carcinoma.